Evidence map›Paper›PMID 21454723›Full record

Trial reportClinical journal of the American Society of Nephrology : CJASN2011

Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.

John M Lachin, Giancarlo Viberti, Bernard Zinman, Steven M Haffner, R Paul Aftring, Gitanjali Paul, Barbara G Kravitz, William H Herman, Rury R Holman, Steven E Kahn and 1 more

Open access · greenAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 6 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 6 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Thiazolidinediones for people with chronic kidney disease and diabetes.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Metformin for preventing the progression of chronic kidney disease.The Cochrane database of systematic reviews · 2024 · on this map
    Pooled it
  4. Pooled it
  5. Metformin monotherapy for adults with type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2020 · on this map
    Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

John M LachinThe Biostatistics Center, The George Washington University, Rockville, MD 20852, USA. jml@bsc.gwu.edu
Giancarlo Viberti
Bernard Zinman
Steven M Haffner
R Paul Aftring
Gitanjali Paul
Barbara G Kravitz
William H Herman
Rury R Holman
Steven E Kahn
ADOPT Study Group
GlaxoSmithKline (United States) · USGeorge Washington University · USKing's College School · GBLunenfeld-Tanenbaum Research Institute · CAOxford Centre for Diabetes, Endocrinology and Metabolism · GBUniversity of Michigan–Ann Arbor · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesIn ADOPT (A Diabetes Outcomes Prevention Trial), initial monotherapy with rosiglitazone provided more durable glycemic control than metformin or glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine differences in albumin excretion, renal function (estimated GFR), and BP over 5 years between treatment groups. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 4351 recently diagnosed, drug-naïve patients with type 2 diabetes were treated and followed for up to 5 years with rosiglitazone, metformin, or glyburide and were examined with periodic assessments of albumin/creatinine ratio (ACR), modification of diet in renal disease (MDRD)-estimated GFR, and BP.

resultsThe ACR rose slowly with metformin. It fell with rosiglitazone and less so with glyburide over the first 2 years, and then rose slowly over time. Estimated GFR (eGFR) with all therapies rose into the high normal range over the first 3 to 4 years, more so with rosiglitazone, and then declined, more so with glyburide. Systolic BP was stable over time, values with rosiglitazone being lower, and diastolic BP declined over time, more so with rosiglitazone than with metformin or glyburide. There was no difference among groups in the incidence of emergent albuminuria (ACR ≥30 mg/g), hypertension, or impaired eGFR (<60 ml/min per 1.73 m(2)).

conclusionsOver a 5-year period, initial monotherapy with rosiglitazone retards the rise of ACR compared with metformin, preserves eGFR compared with glyburide, and lowers BP relative to both comparators.

Indexed as

AdultAgedAlbuminuriaBlood GlucoseBlood PressureCreatinineDiabetes Mellitus, Type 2Diabetic NephropathiesFemaleFollow-Up StudiesGlomerular Filtration RateGlyburideGlycated HemoglobinHumansHypoglycemic AgentsKidneyBlood GlucoseCreatinineGlyburideGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsMetforminRosiglitazoneThiazolidinediones

Identifiers

PMID21454723
PMCPMC3087768
OpenAlexW2150022402

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.